Printer Friendly

FDA Approves AMITIZA, Chronic Idiopathic Constipation Agent - Sucampo and Takeda Pharmaceuticals to Begin Joint Promotion in Spring.

Tokyo, Japan, Feb 1, 2006 - (JCN) - Pharmaceutical announced on February 1 that its US sales partner Sucampo Pharmaceuticals have obtained approval for AMITIZA capsules (lubiprostone), an oral treatment of chronic idiopathic constipation in adults, from the US Food and Drug Administration (FDA).

AMITIZA, which is discovered by Sucampo Pharmaceuticals, is the world's first selective chloride channel activator indicated for treating chronic idiopathic constipation.

Going forward, Sucampo Pharmaceutiacls, Takeda Pharmaceuticals North America and Takeda Pharmaceuticals America will be jointly marketing AMITIZA. The new agent will be available in the US in spring 2006.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Feb 2, 2006
Words:102
Previous Article:OncoTherapy Science, Carna Biosciences, CrystalGenomics to Collaborate in Development of Low-molecular Drug for Cancer.
Next Article:National Institute of Information and Communications Technology, JVC Develop 8-megapixel High-resolution Robotics Technology.


Related Articles
Persistence of abdominal symptoms after successful surgery for idiopathic slow transit constipation. (Review Article).
Takeda Pharmaceutical, Santhera Pharmaceuticals to Collaborate to Develop and Commercialize Idebenone, Drug Candidate for Friedreich's Ataxia.
Takeda Pharmaceutical Wins Patent Infringement Case on ACTOS in US.
Massive fecal impaction presenting with megarectum and perforation of a stercoral ulcer at the rectosigmoid junction.
Takeda Announces Start of Phase 3 Clinical Program in the U.S.of Fixed Dose Combination Product of Actos(R) + TAK-536for Treatment of Patients with...
Takeda Announces Positive Opinion from European Regulatory Authorities for Combination Use of Actos(R) with Insulin for Type 2 Diabetes.
Gastroparesis.
A Once-weekly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent, Was Approved.
NEUROMED LICENSES PHASE 3 CHRONIC PAIN PRODUCT FROM ALZA.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters